Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.
作者信息
Martinelli Silvia, Maffei Rossana, Fiorcari Stefania, Quadrelli Chiara, Zucchini Patrizia, Benatti Stefania, Potenza Leonardo, Luppi Mario, Marasca Roberto
机构信息
Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
出版信息
Haematologica. 2018 Dec;103(12):e598-e601. doi: 10.3324/haematol.2017.187070. Epub 2018 Jul 5.
Abstract
摘要
相似文献
1
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.
Haematologica. 2018 Dec;103(12):e598-e601. doi: 10.3324/haematol.2017.187070. Epub 2018 Jul 5.
2
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Oncotarget. 2017 Mar 7;8(10):16259-16274. doi: 10.18632/oncotarget.15180.
3
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Front Immunol. 2021 Mar 15;12:608625. doi: 10.3389/fimmu.2021.608625. eCollection 2021.
4
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28.
5
Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
PLoS One. 2017 Mar 3;12(3):e0172858. doi: 10.1371/journal.pone.0172858. eCollection 2017.
6
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Haematologica. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.
7
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.
8
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
9
Idelalisib.
Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12.
10
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Leukemia. 2019 Jun;33(6):1427-1438. doi: 10.1038/s41375-018-0318-3. Epub 2018 Dec 20.
引用本文的文献
1
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges.
Front Pharmacol. 2025 Jan 3;15:1517972. doi: 10.3389/fphar.2024.1517972. eCollection 2024.
2
Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia.
Hemasphere. 2023 Feb 22;7(3):e840. doi: 10.1097/HS9.0000000000000840. eCollection 2023 Mar.
3
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939.
4
Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.
Front Oncol. 2021 Dec 17;11:785855. doi: 10.3389/fonc.2021.785855. eCollection 2021.
5
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
6
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients.
Cancers (Basel). 2021 Nov 4;13(21):5535. doi: 10.3390/cancers13215535.
7
Cytomegalovirus in Haematological Tumours.
Front Immunol. 2021 Oct 18;12:703256. doi: 10.3389/fimmu.2021.703256. eCollection 2021.
8
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.
Cancer Immunol Immunother. 2021 Dec;70(12):3693-3700. doi: 10.1007/s00262-021-02988-3. Epub 2021 Jun 25.
9
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Front Immunol. 2021 Jan 20;11:595818. doi: 10.3389/fimmu.2020.595818. eCollection 2020.
10
Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks.
Sci Rep. 2021 Jan 11;11(1):322. doi: 10.1038/s41598-020-79121-4.
本文引用的文献
1
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Future Oncol. 2018 Sep;14(22):2265-2277. doi: 10.2217/fon-2017-0528. Epub 2018 Mar 23.
2
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Clin Infect Dis. 2018 Jan 6;66(1):140-148. doi: 10.1093/cid/cix687.
3
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Haematologica. 2017 Oct;102(10):1629-1639. doi: 10.3324/haematol.2017.164103. Epub 2017 Aug 3.
4
Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia.
Medicine (Baltimore). 2017 Jul;96(30):e7243. doi: 10.1097/MD.0000000000007243.
5
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Cancer Cell. 2017 Jun 12;31(6):731-733. doi: 10.1016/j.ccell.2017.05.004. Epub 2017 May 25.
6
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):385-91. doi: 10.1016/j.clml.2015.02.019. Epub 2015 Feb 19.
7
B cell receptor signaling in chronic lymphocytic leukemia.
Trends Immunol. 2013 Dec;34(12):592-601. doi: 10.1016/j.it.2013.07.002. Epub 2013 Aug 5.
8
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.
9
PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.
Blood. 2010 Mar 18;115(11):2203-13. doi: 10.1182/blood-2009-07-232330. Epub 2010 Jan 15.
10
Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Clin Infect Dis. 2009 Dec 15;49(12):1777-83. doi: 10.1086/648423.
Zotero 插件